Indegene — Q3 FY25 earnings call

Call held 31 Jan 2025

Management summary

Indegene reported a resilient Q3 FY25 with steady sequential revenue growth and significant margin expansion. The company is benefiting from a 'cautious recovery' in the biopharma industry, with strong renewal rates and a robust pipeline of mid-tier clients. Management is successfully leveraging GenAI and automation to offset wage hikes and improve revenue per employee, even as total headcount sees a strategic shift toward domain-heavy roles.

Highlights

  • Revenue reached ₹720.4 crores (INR 7,204 million), representing 7% YoY and 4.9% QoQ growth.

  • EBITDA margin expanded to 20.8%, up 240 bps sequentially, driven by productivity and automation.

  • PAT stood at ₹109.7 crores (INR 1,097 million), an improvement of 19.6% QoQ.

  • Active client base grew to 75 from 68, with USD 1 million+ clients increasing to 38.

  • Won five key expansion deals with annual contract values (ACV) between $2 million and $4 million each.

  • Cash and cash equivalents remained strong at over ₹1,500 crores.

  • Adjusted EBITDA margin (excluding one-time M&A items) was healthy at 20.5%.

Key financials

  1. Revenue ₹720.4 Cr +7%YoY
  2. EBITDA Margin 20.8%
  3. PAT ₹109.7 Cr +19.6%QoQ
  4. PAT Margin 15.2%
  5. Active Clients 75 +10.3%QoQ

What they filed

Q1 FY27: revenue up 33.2%, net profit up 33.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue282 287 267 256 307 +9%290 +1%368 +38%341 +33%
EBITDA46 52 40 37 71 +54%38 −27%103 +158%60 +62%
Net profit45 50 54 45 60 +33%35 −30%72 +33%60 +33%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Enterprise Businesses (Commercial & Medical)
    3.7% QoQ Growth
  • Omnichannel Activation & Others
    11.8% QoQ Growth

Guidance & targets

Revenue

  • New Deal Contribution Revenue · Q4 FY25 · High confidence $2 million to $4 million ACV each
    we won five key deals on expansion... with deal sizes of 2 million to 4 million ACV each, which will go live in the coming month or two and start contributing revenues in the upcoming quarters.

    — Manish Gupta, Chairman & CEO

Market Share

  • Omnichannel Revenue Concentration Market Share · Current · Medium confidence 70% to 80%

    From 55% today

    Today we have I would say six to seven logos in omnichannel activation which is getting us give or take a little between 70% to 80% of the revenues in that segment.

    — Suhas Prabhu, CFO

Other

  • M&A Target Size Other · Next few quarters · Medium confidence $2 million to $50 million revenue
    What we have right now in the pipeline are I would call all of them being sub-$50-$60 million revenue all the way from $2 to $50 million type of revenue range right now.

    — Manish Gupta, Chairman & CEO

Risks & concerns

  • Slower large-scale expansion with top 20 customers

    medium

    Pursuit of large-scale expansion with top 10-20 customers is progressing slower than originally anticipated.

    Management acknowledged

  • Downward pressure on drug pricing (US Administration)

    medium

    While seen as a long-term tailwind for outsourcing, it creates near-term uncertainty regarding client planning cycles.

    Both acknowledged

  • Declining offshore mix

    low

    Management attributes the 300bps drop in offshore mix to recent onsite-heavy acquisitions and the initial change-management phase of new projects.

    Analyst downplayed

Areas of evasion (1)

  • Specific breakdown of 1-5 million vs 5-10 million client categories was not provided beyond directional trends.

Q&A highlights

3 direct
Veeva vs. Salesforce Tug of War Direct
Actually there could be a net positive... if somebody is changing the platform, then of course there's a lot of technology implementation work which requires your tech capabilities and domain expertise.

Clarifies that platform competition in the CRM space creates service opportunities for Indegene rather than competitive threats.

Asked by Abhishek Kumar, JM Financial

Headcount Reduction vs. Automation Direct
The low hanging fruit I would say in this example is the code automation versus say something much more complex... which is the medical writing... the proportion of people with the domain knowledge would be increasing.

Explains the divergence between total headcount (down) and domain-expert headcount (up), signaling a shift toward higher-value, non-commoditized services.

Asked by Punit Pujara, Helios Capital

Impact of US Drug Pricing Reforms Direct
With more pressure on drug pricing, typically you don't have an option. You just have to become more efficient... We typically end up benefiting from that.

Positions drug pricing pressure as a structural tailwind that forces biopharma companies to outsource to efficient digital-first partners like Indegene.

Asked by Abhishek Bhandari, Nomura

2 min read 5 chapters

Detailed narrative

Margin Expansion Through Operational Efficiency

Indegene delivered a strong EBITDA margin of 20.8% in Q3 FY25, a sequential improvement of 240 basis points. This expansion was primarily driven by productivity initiatives, better capacity management, and the successful absorption of July wage hikes through automation. Even after excluding a net ₹2.2 crore positive impact from M&A-related write-backs and write-offs, the adjusted EBITDA margin remained robust at 20.5%.

Strategic Shift in Client Mix

The company is seeing significant traction in the '20 to 100' pharma cohort, which management identifies as a key growth engine. While top 20 pharma accounts remain the core (with the largest account nearing a $50 million run rate), mid-tier clients are increasingly adopting Indegene's centralized operating models. The number of active clients rose from 68 to 75 this quarter, reflecting successful penetration into this mid-market segment.

Automation Redefining the Delivery Model

Management highlighted a deliberate shift in their workforce composition, where GenAI is automating low-complexity tasks like HTML coding. This has led to a reduction in total delivery headcount while simultaneously increasing the number of employees with specialized healthcare and medical expertise. This shift is intended to improve revenue per employee and protect margins as the company scales.

M&A Discipline and Governance

The quarter saw the final settlement of earnouts for CultHealth and the first milestone for Trilogy, resulting in a ₹15.7 crore write-back. Conversely, the company wrote off a ₹13.5 crore loan to TriloDocs due to insufficient progress. Management defended their M&A governance, noting that these smaller, entrepreneurial acquisitions are structured with performance-linked earnouts to mitigate risk and avoid high upfront costs.

Industry Macro and 2025 Outlook

Following a weak 2023 and a modest 2024 (4-5% industry growth), management views 2025 as a year of 'cautious recovery.' Most major client engagements due for renewal this quarter were successfully renewed with a net positive rate. The pipeline is reportedly stronger than the previous year, supported by a slew of new product launches in the biopharma sector and a continued push for commercial efficiency.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls